#38–Francisco Gonzalez-Lima, Ph.D.: Alzheimer’s disease & the vascular hypothesis

KEYPOINTS

• 01

  Late-onset Alzheimer's as a neuronal energy crisis

  Gonzalez-Lima, a UT Austin neuroscientist working in pharmacology, toxicology and psychology for about 27 years, was introduced to the field by Jack de la Torre about 25 years earlier. Their vascular hypothesis holds that the core problem in late-onset Alzheimer's is a progressive shortfall of energy to neurons, driven by reduced blood flow. In this view, plaques and tangles are not the primary cause. Attia presents it as a credible alternative to the dominant amyloid view, not a settled answer.

• 02

  Alzheimer's original patient was not typical

  Alois Alzheimer's 1907 report described a woman of about 51 who died in 1906 after years of dementia. Attia notes she likely had a rare early-onset genetic form, such as a PSEN1 or PSEN2 mutation, which accounts for under 1% of cases, though this has never been confirmed. Meanwhile Oskar Fischer's group in Prague studied 'senile dementia' in people in their 60s–80s, the common late-onset form.

• 03

  Blood flow to the brain falls with age

  Gonzalez-Lima says brain blood supply drops by about 20% between ages 22 and 60, roughly half a percent a year. Arterial stiffening and atherosclerosis in the large arteries, such as the carotids, show up as rising blood pressure. Guidelines now aim for under 120/80, compared with about 135/90 that used to be accepted. He calls atherosclerosis a major risk factor.

• 04

  Function matters more than structure

  Structural scans show anatomy. Functional imaging such as FDG-PET, which grew out of earlier metabolic-mapping work, shows how hard brain regions are working. Attia says many patients don't understand the difference because doctors rarely explain it. Much of Gonzalez-Lima's career has been spent mapping brain metabolism and function.

• 05

  The brain is uniquely vulnerable to energy shortfalls

  At about 2% of body weight, the brain uses about 20% of the body's energy. Its circuits are highly convergent and redundant, which hides early losses until function visibly fails.

• 06

  Cytochrome oxidase is reduced in Alzheimer's brains

  His 2001 study used brains collected within about three hours of death, a very short post-mortem interval, through the Sun City Health Center in Arizona. It found reduced activity of cytochrome oxidase (complex IV), the final, rate-limiting enzyme of the electron transport chain that reduces oxygen to water and drives ATP production. Regions connected to damaged areas also declined, a functional change that standard pathology misses.

• 07

  Partial inhibition of complex IV mimics hypoperfusion

  Inhibiting cytochrome oxidase by more than about 40% kills an organism, which is how cyanide works. His lab used very low doses to create 'functional hypoperfusion' without killing animals. Attia notes duration matters as well as degree: 40% for seconds differs from 40% for minutes.

• 08

  Methylene blue can boost mitochondrial respiration at low doses

  Paul Ehrlich studied it in the 1880s and developed the 'magic bullet' idea, because it concentrates in nerve tissue. The first synthetic medicines, including chlorpromazine around 1950, derived from it. At low doses it shuttles electrons and helps respiration. At high doses it becomes a pro-oxidant, a 'hormetic', two-phase dose response. It treats methaemoglobinaemia at low doses but can cause it at high ones. It was once used for bladder infections, and its half-life is about 12 hours.

• 09

  Near-infrared light also targets cytochrome oxidase

  Cytochrome oxidase absorbs near-infrared photons. His group delivers 1,064 nm laser light through the forehead, a wavelength that penetrates deeper but is rarely studied in biochemistry. He says this improves mitochondrial respiration in the targeted brain tissue. Studies are ongoing with NIH BRAIN Initiative and aging-related funding.